Imaging in Myeloma with Focus on Advanced Imaging Techniques

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2019 Jan 4

PMID 30604631

Citations 11

Authors

Tara Barwick

Laure Bretsztajn

Kathryn Wallitt

Dimitri Amiras

Andrea Rockall

Christina Messiou

Affiliations

Soon will be listed here.

Abstract

In recent years, there have been major advances in the imaging of myeloma with whole body MRI incorporating diffusion-weighted imaging, emerging as the most sensitive modality. Imaging is now a key component in the work-up of patients with a suspected diagnosis of myeloma. The International Myeloma Working Group now specifies that more than one focal lesion on MRI or lytic lesion on whole body low-dose CT or fludeoxyglucose (FDG) PET/CT fulfil the criteria for bone damage requiring therapy. The recent National Institute for Health and Care Excellence myeloma guidelines recommend imaging in all patients with suspected myeloma. In addition, there is emerging data supporting the use of functional imaging techniques (WB-DW MRI and FDG PET/CT) to predict outcome and evaluate response to therapy. This review summarises the imaging modalities used in myeloma, the latest guidelines relevant to imaging and future directions.

Citing Articles

Review of whole-body magnetic resonance imaging in multiple myeloma.

Perillo T, Giorgio C, Fico A, Perrotta M, Serino A, Cuocolo R Jpn J Radiol. 2024; 42(12):1381-1391.

PMID: 39088009 DOI: 10.1007/s11604-024-01635-y.

Photon Counting Detector Computed Tomography: A New Frontier of Myeloma Bone Disease Evaluation.

Cook J, Rajendran K, Ferrero A, Dhillon P, Kumar S, Baffour F Acta Haematol. 2023; 146(5):419-423.

PMID: 37339614 PMC: 10568597. DOI: 10.1159/000531461.

Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI.

Santoni A, Simoncelli M, Franceschini M, Ciofini S, Fredducci S, Caroni F J Pers Med. 2022; 12(11).

PMID: 36579605 PMC: 9696713. DOI: 10.3390/jpm12111885.

Modern imaging techniques for monitoring patients with multiple myeloma.

Pop V, Tomoaia G, Parvu A Med Pharm Rep. 2022; 95(4):377-384.

PMID: 36506611 PMC: 9694753. DOI: 10.15386/mpr-2215.

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?.

Zukovs R, Antke C, Mamlins E, Sawicki L, Mohring A, Lopez Y Niedenhoff D BMC Med Imaging. 2022; 22(1):63.

PMID: 35379187 PMC: 8981746. DOI: 10.1186/s12880-022-00788-4.

References

Chenevert T, Stegman L, Taylor J, Robertson P, GREENBERG H, Rehemtulla A . Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000; 92(24):2029-36. DOI: 10.1093/jnci/92.24.2029. View

Schirrmeister H, Buck A, Bergmann L, Reske S, Bommer M . Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm. 2003; 18(5):841-5. DOI: 10.1089/108497803770418382. View

Horger M, Claussen C, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M . Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol. 2005; 54(2):289-97. DOI: 10.1016/j.ejrad.2004.04.015. View

Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr J . Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25(9):1121-8. DOI: 10.1200/JCO.2006.08.5803. View

Kropil P, Fenk R, Fritz L, Blondin D, Kobbe G, Modder U . Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2007; 18(1):51-8. DOI: 10.1007/s00330-007-0738-3. View

Baur-Melnyk A, Buhmann S, Becker C, Schoenberg S, Lang N, Bartl R . Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008; 190(4):1097-104. DOI: 10.2214/AJR.07.2635. View

Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G . 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. In Vivo. 2008; 22(4):513-7. View

Gleeson T, Moriarty J, Shortt C, Gleeson J, FitzPatrick P, Byrne B . Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2008; 38(3):225-36. DOI: 10.1007/s00256-008-0607-4. View

Kim P, Hicks R, Wirth A, Ryan G, Seymour J, Prince H . Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys. 2008; 74(3):740-6. DOI: 10.1016/j.ijrobp.2008.08.037. View

10.

Shortt C, Gleeson T, Breen K, McHugh J, OConnell M, OGorman P . Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009; 192(4):980-6. DOI: 10.2214/AJR.08.1633. View

11.

Bartel T, Haessler J, Brown T, Shaughnessy Jr J, van Rhee F, Anaissie E . F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114(10):2068-76. PMC: 2744568. DOI: 10.1182/blood-2009-03-213280. View

12.

Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss L . Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009; 34(9):576-84. DOI: 10.1097/RLU.0b013e3181b06bc5. View

13.

Bauerle T, Hillengass J, Fechtner K, Zechmann C, Grenacher L, Moehler T . Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology. 2009; 252(2):477-85. DOI: 10.1148/radiol.2522081756. View

14.

Hillengass J, Fechtner K, Weber M, Bauerle T, Ayyaz S, Heiss C . Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010; 28(9):1606-10. DOI: 10.1200/JCO.2009.25.5356. View

15.

Haznedar R, Aki S, Akdemir O, Ozkurt Z, Ceneli O, Yagci M . Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011; 38(6):1046-53. DOI: 10.1007/s00259-011-1738-8. View

16.

Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M . Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011; 196(6):W790-5. DOI: 10.2214/AJR.10.5979. View

17.

Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A . Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011; 118(23):5989-95. DOI: 10.1182/blood-2011-06-361386. View

18.

Pearce T, Philip S, Brown J, Koh D, Burn P . Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI. Br J Radiol. 2012; 85(1016):1102-6. PMC: 3587069. DOI: 10.1259/bjr/30649204. View

19.

Hillengass J, Ayyaz S, Kilk K, Weber M, Hielscher T, Shah R . Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica. 2012; 97(11):1757-60. PMC: 3487452. DOI: 10.3324/haematol.2012.065359. View

20.

Derlin T, Peldschus K, Munster S, Bannas P, Herrmann J, Stubig T . Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol. 2012; 23(2):570-8. DOI: 10.1007/s00330-012-2600-5. View